RAS Drug Nearly Doubles Survival in Metastatic Pancreatic Cancer David Brzostowicki June 03, 2026

https://www.medscape.com/viewarticle/ras-drug-nearly-doubles-survival-metastatic-pancreatic-2026a1000ihe?ecd=mkm_ret_260614_mscpmrk_onc_mai_pancreatic-cancer_etid8418619&uac=148436CN&impID=8418619 An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients with previously treated metastatic disease.